Identification of VRK1 as a Novel Potential Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
Xiaoyan He,Guozhen Zai,Lidan Zhou,Shengyang Chen,Guizhi Wang
DOI: https://doi.org/10.2147/jir.s452505
IF: 4.5
2024-03-14
Journal of Inflammation Research
Abstract:Xiaoyan He, 1 Guozhen Zai, 1 Lidan Zhou, 2 Shengyang Chen, 3 Guizhi Wang 1 1 Department of Pathology, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 2 Department of Radiology, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 3 Department of Hepatobiliary Pancreatic Surgery, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China Correspondence: Guizhi Wang, Email Background: Research has indicated that VRK1 is essential for the tumor cell cycle. However, its prognostic and immunotherapeutic predictive significance has not been documented in hepatocellular carcinoma (HCC). Methods: The TCGA, ICGC, and GSE14520 datasets were used to investigate VRK1 expression and its predictive significance of survival outcomes. The qRT-PCR and immunohistochemistry (IHC) were used to confirm the findings. The immunotherapeutic response of VRK1 was anticipated by the IMvigor210 cohort. Lastly, the association between immune infiltration, m6A modification, and functional enrichment of differentially expressed genes (DEGs) was investigated in connection to VRK1 expression. Results: VRK1 expression was markedly elevated on both the mRNA and protein levels in HCC. In HCC patients, a high expression of VRK1 was linked to a poor prognosis. Furthermore, there was a substantial positive correlation seen between increased VRK1 expression and the response rate to anti-PD-L1 immunotherapy. Relationships between VRK1 and m6A-related genes as well as different immune cells were shown by correlation studies. Lastly, enrichment analysis revealed a tight relationship between VRK1 and important biological functions, including DNA replication, cell cycle control, and fatty acid metabolism. Conclusion: Our research reveals the potential of VRK1 as a novel biomarker for prognosis and immunotherapy response in HCC patients. Keywords: VRK1, immune infiltration, immunotherapy, m6A, HCC A member of the vaccine-related kinase (VRK) family of serine/threonine protein kinases, VRK1 exhibits unusual activity similar to that of nucleosome kinase, chromatin kinase Mars, or Ser-Thr kinase. 1 Through stable and direct interactions with various chromatin proteins implicated in carcinogenesis, VRK1 can take part in biological processes on the cell cycle, apoptosis, and autophagy regulation. 2 Research has demonstrated that VRK1 was significantly expressed in a large number of human malignancies and could influence patient prognosis. High VRK1 expression was closely associated with poor prognosis of bladder cancer patients, while down-regulation of VRK1 significantly inhibited bladder cancer cell proliferation. 3 The lung squamous cell carcinoma cells' motility, apoptosis, proliferation, and cell cycle progression were all greatly impacted by the downregulation of VRK1, which implies that VRK1 is a good therapy target. 4 By initiating the p53 signaling pathway, luteolin could decrease the expression of VRK1, causing cell proliferation to be inhibited and apoptosis and cell cycle arrest at G2/M in ovarian cancer. 5 In HCC, by regulating the amounts of cell cycle regulators linked to the G1/S transition, VRK1 encouraged tumor development. 6 Unfortunately, no research has documented a connection between VRK1, immune cell infiltration, and the response to immunotherapy in HCC, which deserves further investigation. In this study, we explored the expression profiles and potential prognostic value of VRK1 in multiple publicly available datasets and further validated them in clinical samples using qRT-PCR and IHC to systematically investigate the relationship between VRK1 and pathological features and clinical prognosis of HCC patients. In addition, the study evaluated the predictive value of VRK1 expression on immunotherapy response in HCC patients. Finally, the study also explored the correlation between VRK1 expression and immune infiltration and m6A-related genes. These findings provide important insights into the potential significance of VRK1 in HCC. We downloaded the normalized expression data as well as relevant clinical features of HCC and normal samples from The Cancer Genome Atlas-LIHC cohort (TCGA, https://xenabrowser.net/ ), International Cancer Genome Consortium-LIRI-JP cohort (ICGC, https://dcc.icgc.org/ ) and Gene Expression Omnibus-GSE14520 (GEO, https://www.ncbi.nlm.nih.gov/geo ) databases, respectively. The log2 (FPKM+1) transformation was used to standardize the transcriptome data. The clinical features of these patients are shown in Supplementary Table S1< -Abstract Truncated-
immunology